Early ablation of newly diagnosed paroxysmal atrial fibrillation (NEWPaAF) versus newly diagnosed persistent atrial fibrillation (NEWPeAF): Comparison of patient populations and ablation outcomes.

Introduction: Little is known about very early atrial fibrillation (AF) ablation after first AF detection.

Methods: We evaluated patients with AF ablation <4 months from newly diagnosed paroxysmal AF (NEWPaAF) and newly diagnosed persistent AF (NEWPeAF). We compared the two patient populations and compared ablation outcomes to those undergoing later ablation.

Very long term outcomes of atrial fibrillation ablation.

Background: Little is known about the very long term durability of atrial fibrillation (AF) ablation.

Objective: The purpose of this study was to evaluate very long term AF ablation outcomes.

Methods: We followed 5200 patients undergoing 7145 ablation procedures.

Internationally validated score to predict the outcome of non-paroxysmal atrial fibrillation ablation: the 'FLAME score'.

Background: The clinical effectiveness of ablating non-paroxysmal atrial fibrillation (non-PAF) relies on proper patient selection. We developed and validated a scoring system to predict non-PAF ablation outcomes.

Methods: Data on 416 non-PAF ablations were analysed using binary logistic regression at a London centre.

Novel Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation.

Objectives: This first-in-human feasibility study was undertaken to translate the novel low-voltage MultiPulse Therapy (MPT) (Cardialen, Inc., Minneapolis, Minnesota), which was previously been shown to be effective in preclinical studies in terminating atrial fibrillation (AF), into clinical use.

Background: Current treatment options for AF, the most common arrhythmia in clinical practice, have limited success.

HPSD ablation for AF high-power short-duration RF ablation for atrial fibrillation: A review.

This manuscript reviews the literature for all in silico, ex vivo, in vitro, in vivo and clinical studies of high-power short-duration (HPSD) radiofrequency (RF) ablations. It reviews the biophysics of RF energy delivery applicable to HPSD and the use of surrogate endpoints to guide the duration of HPSD ablations. In silico modeling shows that a variety of settings in power, contact force and RF duration can result in the same surrogate endpoint value of ablation index and several HPSD combinations produce lesion volumes similar to a low-power long-duration (LPLD) RF application.

High-power, short-duration atrial fibrillation ablations using contact force sensing catheters: Outcomes and predictors of success including posterior wall isolation.

Background: Little is known about the long-term outcomes and predictors of success of high-power, short-duration (HPSD) contact force (CF) atrial fibrillation (AF) ablations.

Objective: The purpose of this study was to determine long-term freedom from AF and predictors of freedom from AF for 50-W, 5- to 15-second CF ablation.

Methods: We examined 4-year outcomes and predictors of freedom from AF after AF ablation for 1250 consecutive patients undergoing HPSD CF ablations.

Low complication rates using high power (45-50 W) for short duration for atrial fibrillation ablations.

Background: Many centers use radiofrequency (RF) energy at 25-35 W for 30-60 seconds. There is a safety concern about using higher power, especially on the posterior wall.

Objective: The purpose of this study was to examine complication rates for atrial fibrillation (AF) ablations performed with high-power, short-duration RF energy.

Catheter ablation for failed surgical maze: comparison of cut and sew vs. non-cut and sew maze.

Purpose: To compare findings in patients undergoing atrial fibrillation(AF) and/or atrial flutter(AFl) ablation after failed cut and sew (CS) vs. non-cut and sew (NCS) surgical maze.

Methods: We compared 10 patients with prior CS to 25 with prior NCS maze undergoing catheter ablation after failed maze.

Atrial fibrillation ablation using very short duration 50 W ablations and contact force sensing catheters.

Purpose: The optimal radiofrequency (RF) power and lesion duration using contact force (CF) sensing catheters for atrial fibrillation (AF) ablation are unknown. We evaluate 50 W RF power for very short durations using CF sensing catheters during AF ablation.

Methods: We evaluated 51 patients with paroxysmal (n = 20) or persistent (n = 31) AF undergoing initial RF ablation.

Impact of obesity on atrial fibrillation ablation: Patient characteristics, long-term outcomes, and complications.

Background: There is an association between obesity and atrial fibrillation (AF). The impact of obesity on AF ablation procedures is unclear.

Objective: The purpose of this study was to evaluate the influence of body mass index (BMI) on patient characteristics, long-term ablation outcomes, and procedural complications.

Ablation of atypical atrial flutters using ultra high density-activation sequence mapping.

Purpose: The purpose of this study was to evaluate ultra high density-activation sequence mapping (UHD-ASM) for ablating atypical atrial flutters.

Methods: For 23 patients with 31 atypical atrial flutters (AAF), we created UHD-ASM.

Results: Demographics age = 65.

Predicting atrial fibrillation ablation outcome: The CAAP-AF score.

Background: Patients with a variety of clinical presentations undergo atrial fibrillation (AF) ablation. Long-term ablation success rates can vary considerably.

Objective: The purpose of this study was to develop a clinical scoring system to predict long-term freedom from AF after ablation.

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.

Aims: Atrial fibrillation ablation requires peri-procedural oral anticoagulation (OAC) to prevent thromboembolic events. There are several options for OAC. We evaluate peri-procedural AF ablation complications using a variety of peri-procedural OACs.